Skip to main content

Table 3 Adverse events related to the study drug (SS, N = 293)

From: Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China

 

Participants (%)

Eventsa

Ocular

46 (15.7)

57

 Conjunctival hyperemia

34 (11.6)

37

 Ocular hyperemia

3 (1.0)

3

 Eye pruritus

3 (1.0)

3

 Dry eye

3 (1.0)

3

 Black eye

2 (0.7)

2

 Eyelash growth

2 (0.7)

2

 Cataract

1 (0.3)

1

 Corneal abscission

1 (0.3)

1

 Ocular secretion

1 (0.3)

1

 Ocular sensory abnormality

1 (0.3)

1

 Eye pain

1 (0.3)

1

 Ocular foreign body sensation

1 (0.3)

1

 Meibomian gland dysfunction

1 (0.3)

1

Systematic

 Dry throat

1 (0.3)

1

  1. a A given participant could have multiple events of the same adverse event